Počet záznamů: 1
The structure-dependent toxicity, pharmacokinetics and anti-tumour activity of HPMA copolymer conjugates in the treatment of solid tumours and leukaemia
- 1.
SYSNO ASEP 0463915 Druh ASEP J - Článek v odborném periodiku Zařazení RIV J - Článek v odborném periodiku Poddruh J Článek ve WOS Název The structure-dependent toxicity, pharmacokinetics and anti-tumour activity of HPMA copolymer conjugates in the treatment of solid tumours and leukaemia Tvůrce(i) Tomalová, Barbora (MBU-M) ORCID
Šírová, Milada (MBU-M) RID, ORCID
Rossmann, Pavel (MBU-M)
Pola, Robert (UMCH-V) RID, ORCID
Strohalm, Jiří (UMCH-V)
Chytil, Petr (UMCH-V) RID, ORCID
Černý, Viktor (MBU-M)
Tomala, Jakub (MBU-M) RID, ORCID
Kabešová, Martina (MBU-M) RID
Říhová, Blanka (MBU-M) RID
Ulbrich, Karel (UMCH-V) RID
Etrych, Tomáš (UMCH-V) RID, ORCID
Kovář, Marek (MBU-M) RID, ORCIDZdroj.dok. Journal of Controlled Release. - : Elsevier - ISSN 0168-3659
Roč. 223, 10 February (2016), s. 1-10Poč.str. 10 s. Jazyk dok. eng - angličtina Země vyd. NL - Nizozemsko Klíč. slova HPMA ; Doxorubicin ; Structure Vědní obor RIV EE - Mikrobiologie, virologie Vědní obor RIV – spolupráce Ústav makromolekulární chemie - Makromolekulární chemie CEP GAP301/11/0325 GA ČR - Grantová agentura ČR ED1.1.00/02.0109 GA MŠMT - Ministerstvo školství, mládeže a tělovýchovy Institucionální podpora MBU-M - RVO:61388971 ; UMCH-V - RVO:61389013 UT WOS 000368788900001 EID SCOPUS 84961346074 DOI 10.1016/j.jconrel.2015.12.023 Anotace Polymer drug carriers that are based on N-(2-hydroxypropyl) methacrylamide (HPMA) copolymers have been widely used in the development and synthesis of high-molecular-weight (HMW) drug delivery systems for cancer therapy. In this study, we compared linear (M-w similar to 27 kDa, Rh similar to 4 nm) and non-degradable star (M-w similar to 250 kDa, R-h similar to 13 nm) HPMA copolymer conjugates bearing anthracycline antibiotic doxorubicin (DOX) bound via pH-sensitive hydrazone bond. We determined the in vitro and in vivo toxicity of both conjugates and their maximum tolerated dose (MTD). We also compared their anti-tumour activity in mouse B-cell leukaemia (BCL1) and a mouse T-cell lymphoma (EL4) model. We found that MTD was higher for the linear conjugate (85 mg DOX/kg) and lower for the star conjugate (22.5 mg DOX/kg). An evaluation of the intestinal barrier integrity using FITC-dextran as a gut permeability tracer proved that no pathology was caused by the MTD of either conjugate. However, free DOX showed some damage to the gut barrier. The therapy of BCL1 leukaemia by both of the polymeric conjugates using the MTD or its fraction (i.e., equitoxic dosage) showed better results in the case of the star conjugate. Pracoviště Mikrobiologický ústav Kontakt Eliška Spurná, eliska.spurna@biomed.cas.cz, Tel.: 241 062 231 Rok sběru 2017
Počet záznamů: 1